CYP1A1 m1 Polymorphism Could Increase Risk for Cervical Cancer in Oral Contraceptive Users

Main Article Content

Mayuree Wongpratate Wannapa Settheetham Ishida Sophida Phuthong Sitakan Natphopsuk

Abstract

Background and Objectives:  HPV infection is the main cause for cervical cancer. However, contraceptive use and genetic background may raise a risk of developing cervical cancer. CYP1A1 plays an important role in carcinogenic detoxification. Therefore, genetic polymorphism in CYP1A1 may affect role of CYP1A1 leading to difference in susceptibility to cancer. The aim of this study was to investigate the association between CYP1A1 m1 polymorphism combined with oral contraceptives and cervical cancer risk in Northeastern Thai women.


Methods:  The case-control study of women volunteers were divided into 2 groups, cervical cancer group (n=204) and healthy control group (n=204). DNA was extracted from white blood cells. CYP1A1 m1 polymorphism was detected by PCR-RFLP. Association between CYP1A1 m1 polymorphism combined with oral contraceptive use and cervical cancer risk was examined by uni-, multivariate logistic regression.


Results:  Carriers of CC genotype of CYP1A1 m1 had 10-fold increased cervical cancer risk among women who take oral contraceptives for 5-10 years (95% CI=0.66-530.47, p=0.0455). 


Conclusions:  Our result suggests that CYP1A1 m1 polymorphism is associated with increased risk of cervical cancer in women who use oral contraceptives for long term.

Article Details

Section
Original Articles

References

1. Sangrajrang S, Laowahutanont P, Sangariyavanich E, Petrith W. (Eds.). Hospital-based cancer registry annual report 2016. Bangkok: Pornsup printing, 2018.
2. Ministry of Public Health. Public Health Statistics A.D.2016. Bangkok: Ministry of Public Health, 2017.
3. Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre): human papillomavirus and related diseases in Thailand. Barcelona: HPV Information Centre, 2017.
4. Natphopsuk S, Settheetham-Ishida W, Sinawat S, Pientong C, Yuenyao P, Ishida T. Risk factors for cervical cancer in northeastern Thailand: detailed analyses of sexual and smoking behavior. Asian Pac J Cancer Prev 2012; 13: 5489-95.
5. Settheetham-Ishida W, Singto Y, Kanjanavirojkul N, Chatchawan U, Yuenyao P, Settheetham D, et al. Co-risk factors for HPV infection in Northeastern Thai women with cervical carcinoma. Asian Pac J Cancer Prev 2004; 5: 383-6.
6. Calhoun ES, McGovern RM, Janney CA, Cerhan JR, Iturria SJ, Smith DI, et al. Host genetic polymorphism analysis in cervical cancer. Clin Chem 2002; 48: 1218-24.
7. Kanjanavirojkul N, Pairojkul C, Yuenyao P, Patarapadungkit N. Risk factors and histological outcome of abnormal cervix with human papilloma infection in northeastern Thai-women. Asian Pac J Cancer Prev 2006; 7: 567-70.
8. Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 2005 28; 227: 115-24.
9. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001; 344: 276-285.
10. Masson LF, Sharp L, Cotton SC, Little J. Cytochrome P-450 1A1 gene polymorphisms and risk of breast cancer: a huge review. Am J Epidemiol 2005; 161: 901-15.
11. Rodriguez-Antona C, Gomez A, Karlgren M, Sim SC, Ingelman-Sundberg M. Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Hum Genet 2010; 127: 1-17.
12. Bozina N, Bradamante V, Lovrić M. Genetic polymorphism of metabolic enzymes cancer risk. Arh Hig Rada Toksikol 2009; 60: 217-42.
13. Cosma G, Crofts F, Taioli E, Toniolo P, Garte S. Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health 1993; 40: 309 –16.
14. Xie S, Luo C, Shan X, Zhao S, He J, Cai Z. CYP1A1 MspI polymorphism and the risk of oral squamous cell carcinoma: evidence from a meta-analysis. Mol Clin Oncol 2016; 4: 660-6.
15. Ding G, Xu W, Liu H, Zhang M, Huang Q, Liao Z. CYP1A1 MspI polymorphism is associated with prostate cancer susceptibility: evidence from a meta-analysis. Mol Biol Rep 2013; 40: 3483-91.
16. Zhuo W, Zhang L, Wang Y, Zhu B, Chen Z. CYP1A1 MspI polymorphism and acute myeloid leukemia risk: meta-analyses based on 5018 subjects. J Exp Clin Cancer Res 2012; 31: 62.
17. Ji YN, Wang Q, Lin XQ, Suo LJ. CYP1A1 MspI polymorphisms and lung cancer risk: an updated meta-analysis involving 20,209 subjects. Cytokine 2012; 59: 324-34.
18. Ding B, Sun W, Han S, Cai Y, Ren M, Shen Y. Cytochrome P450 1A1 gene polymorphisms and cervical cancer risk: A systematic review and meta-analysis. Medicine (Baltimore) 2018; 97: e0210.
19. Sugawara T, Nomura E, Sagawa T, Sakuragi N, Fujimoto S. CYP1A1 polymorphism and risk of gynecological malignancy in Japan. Int J Gynecol Cancer 2003; 13: 785-90.
20. Juárez-Cedillo T, Vallejo M, Fragoso JM, Hernández-Hernández DM, Rodríguez-Pérez JM, Sánchez-García S. et al. The risk of developing cervical cancer in Mexican women is associated to CYP1A1 MspI polymorphism. Eur J Cancer 2007; 43: 1590-5.
21. Abbas M, Srivastava K, Imran M, Banerjee M. Association of CYP1A1 gene variants rs4646903 (T>C) and rs1048943 (A>G) with cervical cancer in a North Indian population. Eur J Obstet Gynecol Reprod Biol 2014; 176: 68-74.
22. Tan YH, Sidik SM, Syed Husain SN, Lye MS, Chong PP. CYP1A1 MspI polymorphism and cervical carcinoma risk in the multi-ethnic population of Malaysia: a case-control study. Asian Pac J Cancer Prev 2016; 17: 57-64.
23. Jain V, Ratre YK, Amle D, Mishra PK, Patra PK. Polymorphism of CYP1A1 gene variants rs4646903 and rs1048943 relation to the incidence of cervical cancer in Chhattisgarh. Environ Toxicol Pharmacol 2017; 52: 188-92.
24. Hussein AG, Pasha HF, El-Shahat HM, Gad DM, Toam MM. CYP1A1 gene polymorphisms and smoking status as modifier factors for lung cancer risk. Gene 2014; 541: 26-30.
25. Newbold RR, Liehr JG. Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res 2000 15; 60: 235-7.
26. Lemon HM, Heidel JW, Rodriguez-Sierra JF. Increased catechol estrogen metabolism as a risk factor for nonfamilial breast cancer. Cancer 1992; 69: 457-65.
27. Liehr JG, Ricci MJ, Jefcoate CR, Hannigan EV, Hokanson JA, Zhu BT. 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Proc Natl Acad Sci USA 1995; 92: 9220-4.
28. Liehr JG, Ricci MJ. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci USA 1996; 93: 3294-6.
29. Matos A, Castelão C, Silva APD, Alho I, Bicho M, Medeiros R, et al. Epistatic interaction of CYP1A1 and COMT polymorphisms in cervical cancer. Oxid Med Cell Longev 2016; 2016: 1-7.
30. Kleine JP, Camargo-Kosugi CM, Carvalho CV, Silva FC, Silva ID. Analysis of CYP1A1 and COMT polymorphisms in women with cervical cancer. Genet Mol Res 2015; 14: 18965-73.
31. Chung SH, Franceschi S, Lambert PF. Estrogen and ERalpha: culprits in cervical cancer? Trends Endocrinol Metab 2010; 21: 504-11.
32. Bolton JL, Thatcher GR. Potential mechanisms of estrogen quinone carcinogenesis. Chem Res Toxicol 2008; 21: 93-101.
33. Vadlamuri SV, Glover DD, Turner T, Sarkar MA. Regiospecific expression of cytochrome P4501A1 and 1B1 in human uterine tissue. Cancer Lett 1998; 122: 143-50.
34. Moodley M, Moodley J, Chetty R, Herrington CS. The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: a review. Int J Gynecol Cancer 2003; 13: 103-10.